Linzagolix Versus Leuprorelin for Fibroid Bleeding

Linzagolix, sold as Yselty in the European Union, is a prescription treatment for moderate to severe fibroid symptoms in adult women of reproductive age. It reduces ovarian hormone production. Whether it is paired with replacement hormones, called add-back therapy, changes the prescribing plan.¹

What did the comparison test?

A 24-week randomized trial studied 287 premenopausal Japanese women, averaging 44. They received linzagolix 200 mg daily or leuprorelin injections every four weeks, 1.88 or 3.75 mg. Neither group received add-back hormones.²

For weeks 6–12, 89.9% versus 90.8% achieved a bleeding-chart score below 10. The trial ruled out its predefined 15-percentage-point loss of effectiveness. This establishes noninferiority, not superiority. Chart points are not millilitres.²

Was bleeding suppressed sooner?

During weeks 2–6, 65.0% versus 26.8% had no recorded bleeding. Later results converged. At 24 weeks, average lumbar-spine bone density fell 5.3% versus 4.2%. Participants had regular cycles; these results do not cover every cause of irregular bleeding.²

Why does the regimen matter?

The EU product information limits 200 mg without add-back hormones to no longer than six months because of bone-density loss. That regimen is intended for short-term use when reducing uterine and fibroid volume is desired.³

Other EU regimens include 100 or 200 mg with add-back hormones, and 100 mg without them in selected circumstances. Get a written treatment schedule.³

Known osteoporosis, pregnancy, breastfeeding and unexplained genital bleeding are contraindications. The label recommends a bone-density scan before treatment for women with bone-loss risk factors, and after one year for all continuing users. Add-back hormones carry their own restrictions.³

What should be decided before starting?

Confirm local prescribing instructions, including pregnancy testing and contraception. Yselty has not been demonstrated to provide contraception, even with add-back therapy. The EU label requires effective nonhormonal contraception for women at risk of pregnancy.³

Our guide to GnRH injections before fibroid surgery covers a different decision: preparing for an operation.

Period, Handled includes a Period Scorecard for bleeding days, product changes, pain interference and tiredness. Bring those dated observations to the treatment review. See the book.